← SEC 公告列表 | FDMT SEC 公告 | 4D Molecular Therapeutics, Inc.（FDMT）

重大事件 即時報告 8-K 2026-06-22

4D Molecular Therapeutics股東會全數通過董事選舉、核數師及高管薪酬議案

於 SEC 網站開啟原文

AI 繁中摘要

🗳️ **4D Molecular Therapeutics 年度股東大會投票結果出爐（8-K）** 4D Molecular Therapeutics（股票代碼：FDMT）於2026年6月17日舉行網上年度股東大會，並於6月22日提交8-K報告披露投票結果。截至紀錄日（4月20日），公司共有約52,274,735股普通股在外流通，會上有44,038,022股參與投票（包括親身或委託）。 **提案一：選舉第三類董事（Class III）** 三名獲提名人均成功當選，任期至2029年股東大會。票數如下（「經紀人非投票」約6,964,792股因未獲指示而不計入結果）： - Nancy Miller-Rich：贊成35,880,028票 / withheld 1,193,202票 - John F. Milligan, Ph.D.：贊成35,778,121 / withheld 1,295,109 - Shawn Cline Tomasello, MBA：贊成30,508,706 / withheld 6,564,524 **提案二：批准核數師** 股東以大比數通過續聘PricewaterhouseCoopers LLP為2026財年獨立註冊會計師事務所： - 贊成43,900,362票 / 反對55,763票 / 棄權81,897票 **提案三：諮詢性高管薪酬** 基於顧問性質（非約束力），通過了公司披露的高管薪酬方案： - 贊成36,065,437票 / 反對940,414票 / 棄權67,379票 / 經紀人非投票6,964,792票 💼 **投資者啟示**：所有議案均順利通過，顯示股東對現有董事會組成、審計安排及薪酬策略持支持態度。尤其是高管薪酬獲逾96%的投票贊成（剔除經紀人非投票），反映管理層與股東利益較為一致。留意公司未來需持續披露臨床進展及研發支出，以維持投資者信心。
展開英文正文 
8-K
 
 
 
 false000165064800016506482026-06-172026-06-17

  

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 
 
 

 
 Date of Report (Date of earliest event reported): June 17, 2026

 

  
 
4D Molecular Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 

 
 
 
 
 
 
 
 

 
 Delaware

 001-39782

 47-3506994

 

 
 (State or Other Jurisdiction
of Incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

 

 
  

  

  

  

  

 

 
 5858 Horton Street
#455

  

 

 
 Emeryville, California

  

 94608

 

 
 (Address of Principal Executive Offices)

  

 (Zip Code)

 

  

 
 
 
 

 
 Registrant’s Telephone Number, Including Area Code: (510) 505-2680

 

  

 
 
 
 

 
 N/A

 

 (Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

 
 
 
 
 
 
 
 

 
 
Title of each class

  

 Trading
Symbol(s)

  

 
Name of each exchange on which registered

 

 
 Common Stock, $0.0001 par value per share

  

 FDMT

  

 Nasdaq Global Select Market

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

  

 
  

 
 Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On June 17, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via the internet. On April 20, 2026, the record date for the meeting, there were 52,274,735 shares of the Company’s common stock outstanding with each such share being entitled to one vote per share.
 
At the Annual Meeting, 44,038,022 shares of the Company’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”). 
 
Proposal 1. The Company’s stockholders elected by a plurality of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected.

 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 NOMINEE

  

 FOR

  

 WITHHELD

  

  

 BROKER NON-VOTES

  

 

 
 Nancy Miller-Rich

  

 35,880,028

  

  

 1,193,202

  

  

  

 6,964,792

  

 

 
 John F. Milligan, Ph.D.

  

 35,778,121

  

  

 1,295,109

  

  

  

 6,964,792

  

 

 
 Shawn Cline Tomasello, MBA

  

 30,508,706

  

  

 6,564,524

  

  

  

 6,964,792

  

 

  
Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
 

 
 
 
 
 
 
 
 
 
 
 
 

 
 FOR

  

 AGAINST

  

  

 ABSTAIN

  

 

 
 43,900,362

  

  

 55,763

  

  

  

 81,897

  

 

  
Proposal 3. The Company’s stockholders approved, on an advisory, non-binding basis, the named executive officers’ compensation as disclosed in the Proxy Statement.
 

 
 
 
 
 
 
 
 
 
 

 
 FOR

  

 AGAINST

  

 ABSTAIN

  

 BROKER NON-VOTES

 

 
 36,065,437

  

 940,414

  

 67,379

  

 6,964,792

 

 
 
 

  

 
  

 SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
 
 
 
 
 

 
  

  

  

 

4D MOLECULAR THERAPEUTICS, INC.
 

 

 
  

  

  

  

 

 
 Date:

 June 22, 2026

 By: 

 /s/Kristian Humer

 

 
  

  

  

 Kristian Humer
Chief Financial Officer